ERBB2 and non-small cell lung carcinoma: Current efforts are focussed on prospective collection of pre-treatment blood samples from early stage HER2+ breast cancer patients and non-small cell lung cancer and melanoma patients scheduled to receive immune checkpoint therapy to provide larger datasets to assess the potential of the functional biomarker assay described in this study.